Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

Dual antiretroviral therapy for HIV infection

(2017) Vicente Soriano et al.   Expert Opinion On Drug Safety

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study

(2017) P Gantner et al.   HIV MEDICINE

Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine

(2017) Alan Winston et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

(2017) Francesca Lombardi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance

(2017) Bluma G. Brenner et al.   VIRUS RESEARCH

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics

(2017) Yao-Chun Hsu et al.   Expert Review of Gastroenterology & Hepatology

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

(2017) Laura Ciaffi et al.   Lancet HIV

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial

(2017) Barbara Rossetti et al.   PLoS One

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

(2016) Hans-Jürgen Stellbrink et al.   AIDS

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration

(2016) Caroline A. Sabin et al.   BMC Medicine

Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study

(2016) Sarah Lilian Pett et al.   CLINICAL INFECTIOUS DISEASES

Brief Report

(2016) Jan van Lunzen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects

(2016) Franco Maggiolo et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study

(2016) Francesca Lombardi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

(2016) J. A. Perez-Molina et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients

(2016) Massimiliano Fabbiani et al.   JOURNAL OF INFECTION

Tenofovir and bone health

(2016) Philip M. Grant et al.   Current Opinion in HIV and AIDS

Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis

(2016) Amit C Achhra et al.   Lancet HIV

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

(2015) Michael P. Girouard et al.   CLINICAL INFECTIOUS DISEASES

Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study

(2015) S. Nozza et al.   CLINICAL MICROBIOLOGY AND INFECTION

Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study

(2015) Enric Pedrol et al.   HIV CLINICAL TRIALS

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

(2015) A Carr et al.   HIV MEDICINE

Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial)

(2015) Cathia Soulié et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

(2015) José R Arribas et al.   LANCET INFECTIOUS DISEASES

Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

(2015) José A Perez-Molina et al.   LANCET INFECTIOUS DISEASES

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV

(2015) K. M. Klassen et al.   OSTEOPOROSIS INTERNATIONAL

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

(2014) Pedro Cahn et al.   LANCET INFECTIOUS DISEASES

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

(2014) Jonathan Z. Li et al.   PLoS One

The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health

(2014) Roger J. Bedimo et al.   PLoS One

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study

(2014) Pedro Cahn et al.   Journal of the International AIDS Society

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients

(2014) Jose Luis Casado et al.   Journal of the International AIDS Society

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

(2014) Martin Fisher et al.   Journal of the International AIDS Society

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)

(2013) S. Di Giambenedetto et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya

(2013) L. Ryom et al.   JOURNAL OF INFECTIOUS DISEASES

Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial

(2013) Takeshi Nishijima et al.   PLoS One

Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis

(2013) Huw Price et al.   PLoS One

Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature

(2013) Amit C Achhra et al.   AIDS Research and Therapy

A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results

(2012) Michael J. Kozal et al.   HIV CLINICAL TRIALS

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

(2011) Babafemi Taiwo et al.   AIDS

HIV Infection, Immune Suppression, and Uncontrolled Viremia Are Associated With Increased Multimorbidity Among Aging Injection Drug Users

(2011) M. L. Salter et al.   CLINICAL INFECTIOUS DISEASES

Examination of Noninferiority, Safety, and Tolerability of Lopinavir/ritonavir and Raltegravir Compared with Lopinavir/ritonavir and Tenofovir/ Emtricitabine in Antiretroviral-Naïve Subjects: The PROGRESS Study, 48-Week Results

(2011) Jacques Reynes et al.   HIV CLINICAL TRIALS